EGFR and non-small cell lung carcinoma: In patients with non-small cell lung cancer, 95.84% of the pharmaceutical antineoplastic expenditure was explained by four therapeutic groups: immunotherapy (33.74%), drugs targeting EGFR-activating mutations (28.36%), pemetrexed (22.16%), and ALK tyrosine kinase inhibitors (11.58%).